Stock of the Day

July 16, 2024

Alnylam Pharmaceuticals (ALNY)

$234.03
+$9.56 (+4.3%)
Market Cap: $30.04B

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals Bull Case

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

  • Alnylam Pharmaceuticals, Inc. recently reported strong financial performance in its most recent quarter, with revenue of $1.29 billion, representing a 66.9% year-over-year increase, and earnings per share of $1.84, which exceeded the consensus estimate of $1.63 by $0.21, demonstrating robust commercial execution and profitability with a net margin of 15.26%.
  • The stock currently trades at $227.02, which is significantly below the consensus price target of $366.65, suggesting substantial potential upside of approximately 61% for investors, supported by a "Moderate Buy" consensus rating from analysts who view the current valuation as attractive relative to the company's growth trajectory.
  • Alnylam Pharmaceuticals, Inc. maintains a diversified portfolio of commercial RNAi therapies, including ONPATTRO, GIVLAARI, OXLUMO, and AMVUTTRA, which address rare diseases with high unmet medical needs, providing a stable revenue base while the company continues to develop next-generation treatments for conditions such as hypertension and Alzheimer's disease.
  • Recent analyst actions, including an upgrade to a "strong-buy" rating by Zacks Research and a "buy" rating from HC Wainwright with a $455.00 price target, indicate growing institutional confidence in the company's ability to capitalize on its RNA interference platform and expand its market share in the biopharmaceutical sector.
  • The company exhibits strong balance sheet health with a current ratio of 3.05 and a quick ratio of 2.99, indicating ample liquidity to fund ongoing research and development initiatives and strategic collaborations with partners such as Regeneron and Roche, which may lead to future revenue streams from licensed products.

Alnylam Pharmaceuticals Bear Case

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

  • Alnylam Pharmaceuticals, Inc. is facing ongoing securities fraud investigations by multiple law firms, including Glancy Prongay Wolke & Rotter LLP and The Law Offices of Frank R. Cruz, which allege possible violations of federal securities laws, posing significant legal and reputational risks that could impact shareholder value and lead to costly litigation.
  • The stock has experienced a significant decline from its 52-week high of $495.55 to the current price of $227.02, reflecting a drop of over 54%, which may indicate broader market concerns about the company's valuation, competitive positioning, or the sustainability of its recent revenue growth rates.
  • Short interest in Alnylam Pharmaceuticals, Inc. has increased to 7,711,495 shares as of September 30, 2026, representing a 7.19% month-over-month increase, suggesting that a growing number of investors are betting against the stock, which could lead to further price volatility and downward pressure on the share price.
  • Recent insider selling activity, including a sale of 1,758 shares by EVP Bryan Supran and previous sales by CEO Yvonne Greenstreet and other executives, may signal a lack of confidence among company leadership in the current stock price or a desire to diversify personal holdings, which could be interpreted negatively by the market.
  • Alnylam Pharmaceuticals, Inc. has a high price-to-earnings ratio of 42.20, which is significantly above the biotechnology sector average, indicating that the stock is priced for continued high growth and may be vulnerable to any disappointment in future earnings or revenue guidance, as seen in the recent cut to full-year revenue guidance due to slower-than-expected sales for AMVUTTRA.
← Previous Stock of the DayNext Stock of the Day →

Recent News